Mouse Pseudomonas Aeruginosa Antigen O6 Monoclonal Antibody

Pseudomonas Aeruginosa antigen O6 Mouse Monoclonal Antibody

Cat. Num. AAA77836

• Reactivity: Pseudomonas aeruginosa
• Applications: Western Blot, ELISA
• Synonyms: Pseudomonas Aeruginosa Antigen O6, Antibody; Pseudomonas Aeruginosa antigen O6 Mouse Monoclonal Antibody; P. Aeruginosa antigen O6, serotype 6; anti-Pseudomonas Aeruginosa Antigen O6 antibody

• Host: Mouse
• Reactivity: Pseudomonas aeruginosa
• Clonality: Monoclonal
• Isotype: lgG2b kappa
• Clone Number: MF23-2
• Specificity: The antibody recognizes the O6 serotype of Pseudomonas aeruginosa.
• Form/Format: Lyophilized purified in PBS pH7.4

• Applicable Applications for anti-Pseudomonas Aeruginosa Antigen O6 antibody: WB (Western Blot), ELISA, Agglutination
• Immunogen: Whole bacteria strain O6
• Preservative: None
• Target: Pseudomonas Aeruginosa antigen O6
• Target Alias: P. Aeruginosa antigen O6, serotype 6
• Preparation and Storage: Lyophilized antibodies can be kept at 4°C for up to 3 months and should be kept at -20°C for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80°C) or kept at 4°C for short-term usage (2 months).; For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy.; To limit antibody loss or degradation, BSA (final concentration 0.02%) and sodium azide (final concentration 0.02%) can be added to the suggested first dilution. It is important to first verify if those preservatives are compatible with your assay.

Related Product Information for anti-Pseudomonas Aeruginosa Antigen O6 antibody

Target Background:
Pseudomonas aeruginosa is a Gram-negative bacterium widely distributed in nature and causing opportunistic infections in humans. P. aeruginosa is an important bacterial pathogen of nosocomial (hospital derived) infections, and it can also cause life threatening diseases in patients with cancer, burn wounds, cystic fibrosis and those that have received immunosuppressive therapy. Classification of P. aeruginosa isolates is an important and routine task in hospitals. The basis for the serotyping system for P. aeruginosa is the differences among the O antigen side chains of lipopolysaccharide (LPS). A large number of O antigen side chains have been established by various investigators around the world which led to the creation of a standardized serotyping system known as the International Antigenic Typing Scheme (IATS) with twenty characterized 0 serotype strains of P. aeruginosa.

References

1. Lam JS-LPS quantitation procedures. 2. Lam JS-Production and characterization of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa. 3. Dasgupta T-Characterization of lipopolysaccharide-deficient mutants of Pseudomonas aeruginosa derived from serotypes 03,05, and 06. 4. Rahim R-Involvement of the rml locus in core oligosaccharide and 0 polysaccharide assembly in Pseudomonas aeruginosa.